We deliver risk-based, GMP-harmonized full-discipline design and engineering solutions dedicated to industrial-scale blood plasma fractionation facilities, integrating process, architectural, HVAC, purified water, and electrical automation engineering as a complete system. Our service scope covers greenfield master site planning, brownfield workshop retrofitting, capacity expansion and compliance upgrading for plasma collection receiving, cold-chain storage, protein separation, virus inactivation, sterile formulation and finished product packaging lines. Tailored to the unique safety and purity requirements of human plasma-derived therapeutics including albumin, immunoglobulins and coagulation factors, our spatial and process design systematically mitigates cross-contamination, pathogen transmission and protein denaturation risks, delivering inherently audit-ready manufacturing infrastructure that balances high recovery yield, occupational biosafety and international regulatory compliance.
Our plasma fractionation plant construction follows four foundational design tenets: biosafety-tiered zoning isolation, closed full-process containment, multi-discipline coordinated utility deployment, and temperature-controlled modular scalability. Differential pressure cascade zoning physically segregates raw plasma receiving, unprocessed bulk storage, cold ethanol fractionation suites, low-pH viral inactivation, nanofiltration polishing and sterile filling zones, establishing one-way segregated circulation routes for personnel, raw plasma intermediates, waste and consumables to eliminate cross-flow risks. Architectural envelopes adopt low-shedding, corrosion-resistant sanitary materials suitable for frequent sanitization, with dedicated cold storage zones engineered with stable low-temperature insulation and leakage containment. Optimized HVAC systems maintain graded cleanliness, precise humidity and negative-pressure containment for biohazard zones; validated WFI and purified water distribution networks support CIP/SIP for all separation skids, while redundant power supply and grounding electrical systems secure uninterrupted low-temperature and aseptic operation. Modular structural frameworks reserve expansion interfaces to accommodate growing plasma feedstock throughput and additional downstream product lines without large-scale structural reconstruction.
All layout zoning, process equipment arrangement, sanitary utility specifications and biosafety control measures fully comply with FDA cGMP, EMA Annex 1, PIC/S, ICH Q-series and WHO guidelines for blood product manufacturing. The design embeds mandatory regulatory requirements including dedicated biohazard waste deactivation stations, independent virus safety testing areas, temperature-monitored cold chain storage, and segregated raw and finished material warehouses. Environmental monitoring, access control and central automation systems fully satisfy 21 CFR Part 11 data integrity mandates, capturing immutable electronic batch records, temperature logs and differential pressure audit trails throughout all production stages. Every engineering module undergoes gap assessment against common inspection observations for plasma fractionation plants, sustaining continuous inspection readiness for cross-border regulatory audits and blood product marketing authorization submissions.
We provide end-to-end full-lifecycle turnkey engineering services including pre-project biosafety risk assessment, process sizing and yield simulation, cross-disciplinary conceptual and detailed design, cleanroom and cold room construction supervision, utility piping and electrical cabinet integration, equipment skid installation, system commissioning, performance verification and complete IQ/OQ/PQ qualification dossier handover. By synchronizing process separation logic with architectural, HVAC, water and electrical disciplines in one unified design scheme, we eliminate late-stage engineering collisions, reduce on-site modification costs and shorten overall project delivery cycles. Clients obtain biosafe, yield-stable and regulation-compliant plasma fractionation facilities that minimize protein loss, cut long-term compliance remediation risks and accelerate factory validation and commercial launch of plasma-derived medicinal products.
